INCREASING THE PERCENTAGE OF WARFARIN-TREATED PATIENTS WITH GOOD TTR CONTROL IN SULTAN ISMAIL HEALTH CLINIC
DOI:
https://doi.org/10.63719/qbulletin.v1i35.279Keywords:
Warfarin, time in therapeutic range, international normalised ratio, quality improvement studyAbstract
Time in therapeutic range (TTR) for warfarin measures the percentage of time the patient’s International Normalised Ratio (INR) is within the therapeutic range, reflecting the quality of anticoagulation control. Poor TTR control increases patients’ risk of thromboembolic events, bleeding, hospitalisations, and mortality. A pre-remedial study revealed that only 58.8% of patients in Sultan Ismail Health Clinic achieved good TTR control (TTR>60%). This study aimed to increase the percentage of patients with good TTR control to 65% within six months, which is the standard set in the Quality Assurance Programme Indicators Manual 2023. In this quality improvement study, patients’ INR levels were collected via Chemolims to assess TTR control, while questionnaires were disseminated to doctors, pharmacists, and patients to study the contributing factors. The contributing factors identified were incomplete patient history taking by prescribers (80.0%), lack of pharmacist counselling (50.0%), non-compliance with the warfarin diet (60.0%), and dosage regimen (20.0%). In Cycle 1, the Warfarin checklist (Warf-Check) was developed to streamline the process of taking patients’ history and the Express Warfarin Calculator (E-Warf) was introduced to expedite the calculation of dosage adjustments. Warfarin extended counselling (Warf-EC) was established to provide more focused counselling sessions for high-risk warfarin patients. Educational sessions were conducted for doctors and pharmacists to enhance their knowledge. In Cycle 2, the Klinik Warfarin Protocol (K-WARF) was developed to guide the management of warfarin therapy. Post-interventional results showed that the percentage of patients achieving good TTR control increased from 58.8% to 68.6% in Cycle 1, and improved to 69.3% in Cycle 2. The Achievable Benefit Not Achieved decreased from 6.2% to -3.6% in Cycle 1 and to -4.3% in Cycle 2. The average number of visits for INR monitoring per patient decreased from six to three visits within six months. We plan to expand our strategies and promote our K-WARF protocol nationwide.
References
1. Camm AJ, Lip GYH, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation—developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14(10):1385–1413. doi:10.1093/europace/eus305.
2. Atrial fibrillation: diagnosis and management [Internet]. National Institute for Health and Care Excellence (NICE); 2021 Jun 30 [cited 2023 Oct 3]. Available from: http://www.nice.org.uk/guidance/cg180/resources/guidance-atrial-fibrillation-the- management-of-atrial-fibrillation-pdf
3. Thrombosis Canada [Internet]. Thrombosiscanada.ca. 2025 [cited 2025 May 6]. Available from: http://thrombosiscanada.ca/clinicalguides/#.
4. Hong KS, Kim YK, Bae HJ, Nam HS, Kwon SU, Bang OY, et al. Quality of anticoagulation with warfarin in Korean patients with atrial fibrillation and prior stroke: A multicenter retrospective observational study. J Clin Neurol. 2017;13(3):273–80.
5. Bernaitis N, Ching CK, Chen L, Hon JS, Teo SC, Davey AK, et al. The Sex, Age, Medical History, Treatment, Tobacco Use, Race Risk (SAMe-TT2R2) score predicts warfarin control in a Singaporean population. J Stroke Cerebrovasc Dis. 2017;26(1):64–9.
6. Lee SL, Ong TJ, Mazlan-Kepli W, Mageswaran A, Tan KH, Abd-Malek AM, et al. Patients’ time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic. World J Cardiol. 2021 Sep 26;13(9):483–92.
7. Krittayaphong R, Chantrarat T, Rojjarekampai R, Jittham P, Sairat P, Lip GYH. Poor time in therapeutic range control is associated with adverse clinical outcomes in patients with nonvalvular atrial fibrillation: a report from the nationwide COOL-AF registry. J Clin Med. 2020 Jun 2;9(6):1698.
8. White HD. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control. Arch Intern Med. 2007 Feb 12;167(3):239–45.
9. Haas S, Ten Cate H, Accetta G, Angchaisuksiri P, Bassand JP, Camm AJ, et al. Quality of vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF registry. PLoS One. 2016 Oct 28;11(10):e0164076.
10. Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvular atrial fibrillation: a record linkage study in a large British population. Heart. 2005 Apr 1;91(4):472 7.
11. Alphonsa A, Sharma KK, Sharma G, Bhatia R. Knowledge regarding oral anticoagulation therapy among patients with stroke and those at high risk of thromboembolic events. J Stroke Cerebrovasc Dis. 2015 Mar 1;24(3):668–72.
12. Li X, Sun S, Wang Q, Chen B, Zhao Z, Xu X. Assessment of patients’ warfarin knowledge and anticoagulation control at a joint physician- and pharmacist-managed clinic in China. Patient Preference and Adherence. 2018 May;Volume 12:783–91.
13. Lane DA, Ponsford J, Shelley A, Sirpal A, Lip GYH. Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational intervention programme. Int J Cardiol. 2006 Jun;110(3):354–8.
14. Shrestha S, Sapkota B, Kumpakha A, Acharya U, Sharma R. Evaluation of patients’ knowledge on warfarin in outpatient pharmacy of a tertiary care cardiac center. BMC Res Notes. 2015 Sep 10;8:429.
15. Shang L, Zhang Y, Zhao Y, Tang B, Hou Y. Contemporary oral anticoagulant therapy of patients with atrial fibrillation in China: status, obstacles, and strategies for improvement. BioSci Trends. 2022;16(5):317–29.
16. Wang C, Yang Z, Wang C, Wang Y, Zhao X, Liu L, et al. Significant underuse of warfarin in patients with nonvalvular atrial fibrillation: results from the China National Stroke Registry. J Stroke Cerebrovasc Dis. 2014 May 1;23(5):1157–63. Qian Y, Zhang J, Li J, Weng Z. A retrospective study on the evaluation of the appropriateness of oral anticoagulant therapy for patients with atrial fibrillation. PLoS One. 2021; 16:e0259199.
17. Young S, Bishop L, Twells L, Dillon C, Hawboldt J, O’Shea P. Comparison of pharmacist- managed anticoagulation with usual medical care in a family medicine clinic. BMC Fam Pract. 2011 Aug 17;12(1):88.
18. Alghadeer SM, Alzahrani AA, Alalayet WY, Alkharashi AA, Alarifi MN. Anticoagulation control of warfarin in pharmacist-led clinics versus physician-led clinics: a prospective observational study. Risk Manag Healthc Policy. 2020 Aug;13:1175–9.
19. Shafie S, Choy EL, Hui W, Noor S. Assessment of the clinical outcomes of warfarin therapy in two models of anticoagulation services [Internet]. [cited 2023 Oct 3]. Available from: https://research.pharmacy.gov.my/system/files/PRR3.1pp.18-25.pdf
20. Hasan SS, Shamala R, Syed IA, Basariah N, Chong DWK, Mei TK, et al. Factors affecting warfarin-related knowledge and INR control of patients attending physician- and pharmacist-managed anticoagulation clinics. J Pharm Pract. 2011 Aug 15;24(5):485–93.
21. Aidit S, Soh YC, Yap CS, Khan TM, Neoh CF, Shaharuddin S, et al. Effect of standardized warfarin treatment protocol on anticoagulant effect: comparison of a warfarin medication therapy adherence clinic with usual medical care. Front Pharmacol. 2017 Nov 9;8:637.
22. Clarkesmith DE, Pattison HM, Lip GYH, Lane DA. Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial. PLoS One. 2013 Sep 9;8(9):e74037.
23. Omer AAA, Kusuma IY, Csupor D, Doró P. Outcomes of pharmacist-led patient education on oral anticoagulant therapy: a scoping review. Res Social Adm Pharm. 2025 Feb 19. doi:10.1016/j.sapharm.2025.02.009.
24. Anticoagulation MTAC (AC-MTAC) Protocol. 2nd edition (2020). Pharmaceutical Services Programme, Ministry of Health Malaysia [Internet]. [cited 2023 Oct 3] Available from: https://pharmacy.moh.gov.my/sites/default/files/document-upload/acmtac-protocol- 2019-revised_1.pdf
25. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236-9.
26. Institute for Clinical Systems Improvement. Antithrombotic Therapy Supplement [Internet]. Bloomington (MN): ICSI; 2013 [cited 2023 Oct 3]. Available from: www.icsi.org
27. Wigle P, Hein B, Bernheisel CR. Anticoagulation: updated guidelines for outpatient management. Am Fam Physician. 2019;100(7):426-34.
28. Klinik Warfarin (K-WARF) Protocol. 2nd edition (2024). Sultan Ismail Health Clinic, Johor Bahru District Health Office [Internet]. [cited 2024 Oct 3] Available from: https://drive.google.com/file/d/1U2Ut7_kSBZFiEI2gjFRAOvANvcchcOhf/view?usp=drive_link


